Heart failure & cardiomyopathies
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM
Study context
- Population
- Symptomatic adults with nonobstructive hypertrophic cardiomyopathy (nHCM)1,088 screened
- Participants
- 580 adults
- Comparison
- Mavacamten vs placebo
- Primary endpoint
- Changes in KCCQ-23 Clinical Summary Score and in peak oxygen consumption (pVO2) on cardiopulmonary exercise testing
- Follow-up
- Baseline to week 48
Methodological detailsphase 3, double-blind, placebo-controlled, 201 sites worldwide, blinded core laboratory dose titration
- Phase 3
- Double-blind
- Placebo-controlled
- 201 sites worldwide
- Blinded core laboratory dose titration
Primary result
As reported in the abstract
Baseline characteristics · baseline
- Age, mean ± SD (years)
- 56 ± 15
- Women
- 46%
- Family history
- 43%
- NYHA class II
- 70%
- NYHA class III
- 30%
- KCCQ-23 Clinical Summary Score, mean
- 58 ± 20
- On beta-blockers
- 77%
- LVEF, mean
- 66% ± 4%
- pVO2, mean (mL/kg/min)
- 18 ± 6
Original publication
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM. JACC Heart Fail. doi:10.
Summarised from the published abstract; every number is checked against it